Enalare Therapeutics Inc. is a privately owned clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from acute respiratory conditions.
February 2nd, 2021
The Company Raises $10 Million to Expand Its Operations and Prepare to Conduct Pivotal Studies of Lead Drug Candidate ENA-001.
January 19th, 2021
The Addition of Dr. Coleman Further Enhances the Company’s Deep Medical, Enterprise Leadership, and Capital Markets Experience.
January 12th, 2021
The Appointments of Professors Albert Dahan MD, PhD and Tong Joo (TJ) Gan MD, MHS, MBA Highlight a World Class Collection of Medical and Pharmaceutical Industry Experts.
November 17th, 2020
The addition of Gino Santini, Bob Yedid, and Joe Petko Significantly Expands Company’s Pharmaceutical and Financial Markets Experience and Capabilities.
November 9th, 2020
Enalare Therapeutics Inc. announced today that it has appointed pharmaceutical industry veteran Daniel Motto as its Chief Business Officer.
October 30th, 2020
Enalare Therapeutics Inc. announced today that it has appointed biopharma industry veteran Herm Cukier as its Executive Chairman of the Board, President, and Chief Executive Officer.
Two Studies on Reversal of Opioid-induced Respiratory Depression by BK-channel Blocker GAL021 in Human Volunteers
Margot Roozekrans, M.D., Rutger van der Schrier, M.D., Pieter Okkerse, M.D., Justin Hay, Ph.D., James F. McLeod, M.D., Albert Dahan, M.D., Ph.D
Joseph F. Cotten, M.D., Ph.D.
Francis J. Golder, Matthew M. Hewitt, James F. McLeod
Rutger van der Schier, Margot Roozekrans, Monique van Velzen, Albert Dahan and Marieke Niesters
GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteers
J. F. McLeod, J. M. Leempoels, S. X. Peng, S. L. Dax, L. J. Myers and F. J. Golder
Hear from our KOL, Dr. Eugene Vortsman
Northwell Health System Practicing Emergency Medicine Specialist
Hear from our KOL, Dr. TJ Gan
Stony Brook University Professor of and Chair, Department of Anesthesiology
April 5th, 2021
Herm Cukier, President and Chief Executive Officer, will be presenting at the BioNJ’s Eleventh Annual BioPartnering Conference. The presentation will be recorded and visible for all registered participants of the conference which is scheduled virtually for May 18th and 19th.
February 3rd, 2021
January 4th, 2021
Herm Cukier, President and Chief Executive Officer, and Daniel Motto, Chief Business Officer, will host one-on-one investor meetings during the Biotech Showcase being held January 11-15, 2021.
- History of Respiratory Stimulants
- Commentary: New Complications Make Treatment of “Opioid” Overdose Challenging
- Commentary: “Ockham’s Razor” Doesn’t Apply to “Opioid” Overdose Death
- Prediction of Opioid-Induced Respiratory Depression on Inpatient Wards Using Continuous Capnography and Oximetry: An International Prospective, Observational Trial
- The Polysubstance Overdose-Death Crisis
- Increase in Fatal Drug Overdoses Across the United States Driven by Synthetic Opioids Before and During the COVID-19 Pandemic
- The problem of postoperative respiratory depression